EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy

Michela Tinelli M, Aine Roddy, Martin Knapp, Celso Arango, Maria Andreina Mendez, James Cusack, Declan Murphy, Roberto Canitano, Bethany Oakley, Vinciane Quoidbach

Journal of Autism and Developmental Disorders · 2024

DOI: 10.1007/s10803-023-05941-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Autism and Developmental Disorders, 2024. Verfasst von Michela Tinelli M und 9 weiteren Autor:innen. Beteiligte Einrichtung: Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK. m.tinelli@lse.ac.uk. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Cost-Benefit Analysis, Autistic Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Commission européenne Office Européen de Lutte Antifraude.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children’s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsyCost-Benefit AnalysisAutistic DisorderHumansChildCarbamazepineSpainIrelandItalyGabapentinOxcarbazepineEnglandMalegamma-Aminobutyric AcidFemaleAmines

Stichwörter der Autor:innen

AutismChildrenCost-effectivenessEpilepsyFamily impactsHealthcare expenditure

Substanzen

AnticonvulsantsCarbamazepineGabapentinOxcarbazepinegamma-Aminobutyric AcidAmines

Autor:innen und Institutionen

  • Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK. m.tinelli@lse.ac.uk.
  • Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.
  • Atlantic Technological University, Sligo, Ireland.
  • Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, School of Medicine, Hospital General Universitario Gregorio Marañón, Universidad Complutense, CIBERSAM, IiSGM, Madrid, Spain.
  • Autistica, London, UK.
  • Kings College London, London, UK.

Förderung

  • Commission européenne Office Européen de Lutte Antifraude

Zitieren

APA

Tinelli M, M., Roddy, A., Knapp, M., Arango, C., Mendez, M. A., Cusack, J., Murphy, D., Canitano, R., Oakley, B., & Quoidbach, V. (2024). Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-023-05941-8

Vancouver

Tinelli M M, Roddy A, Knapp M, Arango C, Mendez MA, Cusack J, et al. Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy. Journal of Autism and Developmental Disorders. 2024. doi:10.1007/s10803-023-05941-8

BibTeX
@article{TinelliM2024,
  author = {Tinelli M, Michela and Roddy, Aine and Knapp, Martin and Arango, Celso and Mendez, Maria Andreina and Cusack, James and Murphy, Declan and Canitano, Roberto and Oakley, Bethany and Quoidbach, Vinciane},
  title = {Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy},
  journal = {Journal of Autism and Developmental Disorders},
  year = {2024},
  doi = {10.1007/s10803-023-05941-8}
}
Kostenlos starten →